Jefferies Financial Group’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
DTC
Jefferies Financial Group's AXSM Position: Q2 2026 in Review
Jefferies Financial Group increased its Axsome Therapeutics (AXSM) stake by 65% in Q2 2026, buying an estimated $2.2M and bringing the position to 25,628 shares worth $6.27M. The position accounts for 0.04% of the portfolio, ranked #339.
Jefferies Financial Group first reported a position in AXSM in Q3 2023 and has held it in 8 quarters since. The position peaked at $44.8M in Q4 2023. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.
- Jefferies Financial Group held 25,628 shares of Axsome Therapeutics worth $6.27M as of Q2 2026.
- Jefferies Financial Group bought 10,128 Axsome Therapeutics shares in Q2 2026, an estimated $2.2M.
- Axsome Therapeutics made up 0.04% of Jefferies Financial Group's portfolio in Q2 2026, its #339 holding.
- Jefferies Financial Group first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 8 quarters since.
- Jefferies Financial Group's Axsome Therapeutics position peaked at $44.8M in Q4 2023.
- 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.
Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.